首页 > 最新文献

Reproductive biomedicine online最新文献

英文 中文
Do faster, do better: frozen embryo transfer outcomes with one-step warming protocol at different embryos stages. 做得越快,做得越好:在不同胚胎阶段采用一步升温方案的冷冻胚胎移植结果。
IF 3.5 2区 医学 Q1 OBSTETRICS & GYNECOLOGY Pub Date : 2025-10-01 Epub Date: 2025-03-04 DOI: 10.1016/j.rbmo.2025.104874
Rossella Fucci, Patrizia Falcone, Francesco Capodanno, Sara Rubini, Andrea Gallinelli, Vincenzo Lofiego, Silvia De Stefani, Mariangela Primiterra, Elisabetta Coccia, Elisabetta Baldi, Simone Palini

Research question: What effect does the use of a rapid warming method of vitrified embryos have on survival and pregnancy?

Design: A comparison of two different warming embryos protocols: long protocol (group 1, n = 486) and a new fast protocol (group 2, n = 413) for blastocyst and cleavage stage frozen embryo transfers at two IVF centres: Assisted Reproductive Technology Centre, Careggi University Hospital Firenze and IVF Unit, 'Cervesi' Hospital Cattolica. Total pregnancy rate was considered primary outcome, and embryo survival rate, clinical pregnancy rate, miscarriage rate, ongoing pregnancy rate and mean time required for warming procedure were considered secondary outcomes.

Results: The same embryo survival rate was observed in the two groups. Total and clinical pregnancy rates seemed to be higher, but not statistically different, in group 2 compared with group 1 (29.5% versus 26.7% and 27.6% versus 22.6%, respectively). Conversely, a statistically significant reduction in miscarriage rate was found in group 2 compared with group 1 (18.0% versus 32.3%, P = 0.009). Similarly, a significant increase in pregnancy rate at 26 gestational weeks or over was observed in group 2 compared with group 1 (66.9% versus 80.3%, P = 0.016). Finally, a difference in time required for warming procedures was found in favour of group 2.

Conclusions: The use of the fast warming protocol is a valid alternative to the classic warming protocol, and allows a reduction in the time needed to carry out the procedure and the workload of embryologists in an IVF laboratory.

研究问题:使用玻璃化胚胎的快速加热方法对存活和怀孕有什么影响?设计:比较两种不同的加热胚胎方案:在两个体外受精中心(辅助生殖技术中心,佛罗伦萨Careggi大学医院和卡托利卡Cervesi医院体外受精部)进行囊胚和卵分裂期冷冻胚胎移植的长方案(第1组, = 486)和新的快速方案(第2组, = 413)。总妊娠率被认为是主要结局,胚胎存活率、临床妊娠率、流产率、持续妊娠率和平均升温所需时间被认为是次要结局。结果:两组胚胎存活率相同。2组总妊娠率和临床妊娠率似乎高于1组,但无统计学差异(分别为29.5%比26.7%和27.6%比22.6%)。相反,与1组相比,2组流产率明显降低(18.0% vs 32.3%, P = 0.009)。同样,与1组相比,2组26孕周及以上的妊娠率显著增加(66.9% vs 80.3%, P = 0.016)。最后,发现加热程序所需的时间差异有利于第2组。结论:使用快速升温方案是经典升温方案的有效替代方案,并且可以减少执行程序所需的时间和体外受精实验室胚胎学家的工作量。
{"title":"Do faster, do better: frozen embryo transfer outcomes with one-step warming protocol at different embryos stages.","authors":"Rossella Fucci, Patrizia Falcone, Francesco Capodanno, Sara Rubini, Andrea Gallinelli, Vincenzo Lofiego, Silvia De Stefani, Mariangela Primiterra, Elisabetta Coccia, Elisabetta Baldi, Simone Palini","doi":"10.1016/j.rbmo.2025.104874","DOIUrl":"10.1016/j.rbmo.2025.104874","url":null,"abstract":"<p><strong>Research question: </strong>What effect does the use of a rapid warming method of vitrified embryos have on survival and pregnancy?</p><p><strong>Design: </strong>A comparison of two different warming embryos protocols: long protocol (group 1, n = 486) and a new fast protocol (group 2, n = 413) for blastocyst and cleavage stage frozen embryo transfers at two IVF centres: Assisted Reproductive Technology Centre, Careggi University Hospital Firenze and IVF Unit, 'Cervesi' Hospital Cattolica. Total pregnancy rate was considered primary outcome, and embryo survival rate, clinical pregnancy rate, miscarriage rate, ongoing pregnancy rate and mean time required for warming procedure were considered secondary outcomes.</p><p><strong>Results: </strong>The same embryo survival rate was observed in the two groups. Total and clinical pregnancy rates seemed to be higher, but not statistically different, in group 2 compared with group 1 (29.5% versus 26.7% and 27.6% versus 22.6%, respectively). Conversely, a statistically significant reduction in miscarriage rate was found in group 2 compared with group 1 (18.0% versus 32.3%, P = 0.009). Similarly, a significant increase in pregnancy rate at 26 gestational weeks or over was observed in group 2 compared with group 1 (66.9% versus 80.3%, P = 0.016). Finally, a difference in time required for warming procedures was found in favour of group 2.</p><p><strong>Conclusions: </strong>The use of the fast warming protocol is a valid alternative to the classic warming protocol, and allows a reduction in the time needed to carry out the procedure and the workload of embryologists in an IVF laboratory.</p>","PeriodicalId":21134,"journal":{"name":"Reproductive biomedicine online","volume":"51 4","pages":"104874"},"PeriodicalIF":3.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144812282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fertility treatment after sexual trauma. 性创伤后的生育治疗。
IF 3.5 2区 医学 Q1 OBSTETRICS & GYNECOLOGY Pub Date : 2025-10-01 Epub Date: 2025-04-22 DOI: 10.1016/j.rbmo.2025.105022
Ido Feferkorn, Assaf Goldberg, Meital Bonchek, Tatiana Beniar, Dana Taron-Amir, Judith Kadouch Kowalsky, Eytan Giladi Yacobi, Talya Shaulov, Mali Salmon-Divon, Foad Azem

Research question: What are the experiences, needs and preferences of women with a history of sexual trauma undergoing fertility treatment?

Design: Women survivors of sexual violence who were previously referred for, underwent or were undergoing fertility treatment were invited to participate in an online survey. Respondents were asked about which screening tool they preferred to gather information about the history of sexual violence, and to rate the significance of specific triggers related to fertility treatment.

Results: A total of 155 women responded to the survey. The preferred screening tool for a history of sexual violence was an intake form (76 women [63%]) followed by direct questioning (20 women [16.5%]). Only 11 women (9%) preferred not to be screened for a history of sexual violence. The triggers with the highest intensity were arm and leg fixation during egg retrieval (66.2% and 66.8% of women respectively graded the trigger as 5/5). Past pregnancy was associated with a reduction in the intensity of triggers, but this was of small magnitude (5.8%). Although 65 women (59%) preferred a female physician to carry out fertility-related procedures, most women accepted the treating physician regardless of gender as long as the physician was trained in trauma-informed care.

Conclusion: Not all triggers related to infertility treatment can be completely avoided; however, a discussion with patients about what may pose a trigger and how to decrease the severity of that trigger is important.

研究问题:有过性创伤史的女性在接受生育治疗时的经历、需求和偏好是什么?设计:邀请曾被转诊、接受或正在接受生育治疗的性暴力妇女幸存者参加一项在线调查。受访者被问及他们更喜欢哪种筛选工具来收集有关性暴力史的信息,并对与生育治疗相关的特定触发因素的重要性进行评分。结果:共有155名女性参与了调查。性暴力史的首选筛查工具是填写表格(76名妇女[63%]),然后直接询问(20名妇女[16.5%])。只有11名妇女(9%)不愿接受性暴力史筛查。其中强度最大的触发因素是取卵时固定手臂和腿(66.2%和66.8%的女性分别将触发因素评为5/5)。既往妊娠与诱发因素强度降低有关,但幅度较小(5.8%)。尽管65名妇女(59%)更喜欢由女医生进行与生育有关的手术,但大多数妇女接受治疗医生,无论性别,只要医生接受过创伤知情护理方面的培训。结论:并非所有不孕不育的相关诱因都可以完全避免;然而,与患者讨论什么可能构成触发因素以及如何降低触发因素的严重程度是很重要的。
{"title":"Fertility treatment after sexual trauma.","authors":"Ido Feferkorn, Assaf Goldberg, Meital Bonchek, Tatiana Beniar, Dana Taron-Amir, Judith Kadouch Kowalsky, Eytan Giladi Yacobi, Talya Shaulov, Mali Salmon-Divon, Foad Azem","doi":"10.1016/j.rbmo.2025.105022","DOIUrl":"10.1016/j.rbmo.2025.105022","url":null,"abstract":"<p><strong>Research question: </strong>What are the experiences, needs and preferences of women with a history of sexual trauma undergoing fertility treatment?</p><p><strong>Design: </strong>Women survivors of sexual violence who were previously referred for, underwent or were undergoing fertility treatment were invited to participate in an online survey. Respondents were asked about which screening tool they preferred to gather information about the history of sexual violence, and to rate the significance of specific triggers related to fertility treatment.</p><p><strong>Results: </strong>A total of 155 women responded to the survey. The preferred screening tool for a history of sexual violence was an intake form (76 women [63%]) followed by direct questioning (20 women [16.5%]). Only 11 women (9%) preferred not to be screened for a history of sexual violence. The triggers with the highest intensity were arm and leg fixation during egg retrieval (66.2% and 66.8% of women respectively graded the trigger as 5/5). Past pregnancy was associated with a reduction in the intensity of triggers, but this was of small magnitude (5.8%). Although 65 women (59%) preferred a female physician to carry out fertility-related procedures, most women accepted the treating physician regardless of gender as long as the physician was trained in trauma-informed care.</p><p><strong>Conclusion: </strong>Not all triggers related to infertility treatment can be completely avoided; however, a discussion with patients about what may pose a trigger and how to decrease the severity of that trigger is important.</p>","PeriodicalId":21134,"journal":{"name":"Reproductive biomedicine online","volume":"51 4","pages":"105022"},"PeriodicalIF":3.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144817443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Digital twins in fertility, assisted reproductive technology and pregnancy: a systematic review. 数字双胞胎在生育,辅助生殖技术和怀孕:系统回顾。
IF 3.5 2区 医学 Q1 OBSTETRICS & GYNECOLOGY Pub Date : 2025-09-29 DOI: 10.1016/j.rbmo.2025.105281
Alexandre Vallée, Gaby Moawad, Anis Feki, Jean-Marc Ayoubi

Digital twins - the term for virtual representations of biological systems - are emerging as promising tools in reproductive medicine. They offer personalized simulations for optimizing fertility, assisted reproductive technology (ART) and pregnancy outcomes. However, their use remains limited and fragmented across diverse applications. A systematic search was conducted in PubMed, EMBASE, Scopus and IEEE Xplore up to July 2025 for this review of the current evidence on digital twins in fertility, ART and pregnancy, identifying applications, outcomes, challenges and future prospects. Original studies that applied digital twins to fertility, ART or pregnancy in human or in-silico models were included in this review. Eight original studies were included, complemented by nine mechanistic or conceptual works. Applications encompassed embryo selection, IVF procedure modelling, placental physiology, pregnancy pharmacokinetics, and intrapartum monitoring. Most studies were predictive or descriptive in nature, static or batch-coupled, and at early stages of validation. Risk of bias ranged from moderate to high due to study design and external validity concerns. Only two studies fulfilled strict digital twin criteria, and the exclusion of borderline studies did not change the overall conclusions. Digital twins hold substantial promise for personalized reproductive care. However, their clinical utility remains largely theoretical. Future work must improve modelling accuracy, data integration and ethical implementation to unlock their full potential.

数字双胞胎——生物系统的虚拟表示——正在成为生殖医学中很有前途的工具。他们为优化生育、辅助生殖技术(ART)和妊娠结局提供个性化模拟。然而,它们的使用仍然是有限的,并且在不同的应用程序中是分散的。系统检索PubMed, EMBASE, Scopus和IEEE explore到2025年7月,对数字双胞胎在生育,ART和怀孕方面的现有证据进行了回顾,确定了应用,结果,挑战和未来前景。本综述纳入了将数字双胞胎应用于人类或计算机模型的生育、抗逆转录病毒治疗或怀孕的原始研究。包括八项原始研究,辅以九项机械或概念研究。应用包括胚胎选择、体外受精过程建模、胎盘生理学、妊娠药代动力学和产时监测。大多数研究本质上是预测性或描述性的,静态或批量耦合的,并且处于验证的早期阶段。由于研究设计和外部效度的考虑,偏倚风险从中度到高度不等。只有两项研究符合严格的数字双胞胎标准,排除边缘性研究并没有改变总体结论。数字双胞胎为个性化生殖护理带来了巨大的希望。然而,它们的临床应用在很大程度上仍停留在理论层面。未来的工作必须提高建模的准确性、数据整合和道德执行,以释放其全部潜力。
{"title":"Digital twins in fertility, assisted reproductive technology and pregnancy: a systematic review.","authors":"Alexandre Vallée, Gaby Moawad, Anis Feki, Jean-Marc Ayoubi","doi":"10.1016/j.rbmo.2025.105281","DOIUrl":"https://doi.org/10.1016/j.rbmo.2025.105281","url":null,"abstract":"<p><p>Digital twins - the term for virtual representations of biological systems - are emerging as promising tools in reproductive medicine. They offer personalized simulations for optimizing fertility, assisted reproductive technology (ART) and pregnancy outcomes. However, their use remains limited and fragmented across diverse applications. A systematic search was conducted in PubMed, EMBASE, Scopus and IEEE Xplore up to July 2025 for this review of the current evidence on digital twins in fertility, ART and pregnancy, identifying applications, outcomes, challenges and future prospects. Original studies that applied digital twins to fertility, ART or pregnancy in human or in-silico models were included in this review. Eight original studies were included, complemented by nine mechanistic or conceptual works. Applications encompassed embryo selection, IVF procedure modelling, placental physiology, pregnancy pharmacokinetics, and intrapartum monitoring. Most studies were predictive or descriptive in nature, static or batch-coupled, and at early stages of validation. Risk of bias ranged from moderate to high due to study design and external validity concerns. Only two studies fulfilled strict digital twin criteria, and the exclusion of borderline studies did not change the overall conclusions. Digital twins hold substantial promise for personalized reproductive care. However, their clinical utility remains largely theoretical. Future work must improve modelling accuracy, data integration and ethical implementation to unlock their full potential.</p>","PeriodicalId":21134,"journal":{"name":"Reproductive biomedicine online","volume":"52 3","pages":"105281"},"PeriodicalIF":3.5,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146182029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk of progesterone elevation in patients with low ovarian reserve using long-acting FSH IVF protocol: a randomized controlled trial. 使用长效FSH IVF方案的低卵巢储备患者黄体酮升高的风险:一项随机对照试验。
IF 3.5 2区 医学 Q1 OBSTETRICS & GYNECOLOGY Pub Date : 2025-09-26 DOI: 10.1016/j.rbmo.2025.105270
Enrico Papaleo, Antonio Quartucci, Mara Zanirato, Daria Marzanati, Valeria Stella Vanni, Edoardo Delfanti, Giulia Bertapelle, Massimo Candiani

Research question: Does the long-acting stimulation protocol with corifollitropin alfa (CFA) followed by daily low-dose recombinant FSH (r-FSH) reduce the risk of premature progesterone elevation (PPE) in women with low ovarian reserve compared with daily high-dose r-FSH?

Design: This randomized controlled trial, conducted from February 2022 to May 2024, enrolled 110 patients who met the Bologna criteria for poor ovarian responders. Participants were randomized into two groups: the intervention group received long-acting CFA followed by daily 150 IU r-FSH from day 8; and the control group received daily 300 IU r-FSH. The primary outcome was the proportion of patients with progesterone ≥1.1 ng/ml on the day of human chorionic gonadotrophin trigger. Secondary outcomes included number of retrieved oocytes, fertilization rate, fresh embryo transfer rate, and pregnancy rate.

Results: A significantly lower rate of PPE was observed in the CFA group compared with the control group [2/56 (3.6%) versus 12/54 (22.2%), respectively]. CFA stimulation was associated with an 89% reduction in the odds of PPE (OR 0.11, 95% CI 0.02-0.55; P = 0.007). Fresh embryo transfer was achieved in 34/52 (65%) patients in the CFA group versus 21/48 (44%) patients in the control group (P = 0.04).

Conclusions: Ovarian stimulation with long-acting CFA plus daily 150 IU r-FSH significantly reduced the risk of PPE and increased the feasibility of fresh embryo transfer in patients with low ovarian reserve. This strategy may offer a better approach for managing PPE, and may improve overall IVF success for this specific patient population.

研究问题:与每日高剂量的r-FSH相比,口服促孕激素(CFA)和每日低剂量重组FSH (r-FSH)的长效刺激方案是否能降低卵巢储备能力低的女性早孕激素升高(PPE)的风险?设计:该随机对照试验于2022年2月至2024年5月进行,纳入了110名符合Bologna标准的卵巢不良反应患者。参与者被随机分为两组:干预组从第8天开始接受长效CFA,随后每日150 IU r-FSH;对照组每天给予300 IU的r-FSH。主要终点是人绒毛膜促性腺激素触发当天孕激素≥1.1 ng/ml的患者比例。次要结果包括卵母细胞数量、受精率、新鲜胚胎移植率和妊娠率。结果:CFA组PPE发生率明显低于对照组[2/56 (3.6%)vs . 12/54(22.2%)]。CFA刺激与PPE发生率降低89%相关(OR 0.11, 95% CI 0.02-0.55; P = 0.007)。CFA组34/52例(65%)患者实现了新鲜胚胎移植,对照组21/48例(44%)患者实现了新鲜胚胎移植(P = 0.04)。结论:卵巢刺激长效CFA加每日150 IU r-FSH可显著降低卵巢储备不足患者发生PPE的风险,提高新鲜胚胎移植的可行性。这种策略可能为管理PPE提供更好的方法,并可能提高这一特定患者群体的整体试管婴儿成功率。
{"title":"Risk of progesterone elevation in patients with low ovarian reserve using long-acting FSH IVF protocol: a randomized controlled trial.","authors":"Enrico Papaleo, Antonio Quartucci, Mara Zanirato, Daria Marzanati, Valeria Stella Vanni, Edoardo Delfanti, Giulia Bertapelle, Massimo Candiani","doi":"10.1016/j.rbmo.2025.105270","DOIUrl":"https://doi.org/10.1016/j.rbmo.2025.105270","url":null,"abstract":"<p><strong>Research question: </strong>Does the long-acting stimulation protocol with corifollitropin alfa (CFA) followed by daily low-dose recombinant FSH (r-FSH) reduce the risk of premature progesterone elevation (PPE) in women with low ovarian reserve compared with daily high-dose r-FSH?</p><p><strong>Design: </strong>This randomized controlled trial, conducted from February 2022 to May 2024, enrolled 110 patients who met the Bologna criteria for poor ovarian responders. Participants were randomized into two groups: the intervention group received long-acting CFA followed by daily 150 IU r-FSH from day 8; and the control group received daily 300 IU r-FSH. The primary outcome was the proportion of patients with progesterone ≥1.1 ng/ml on the day of human chorionic gonadotrophin trigger. Secondary outcomes included number of retrieved oocytes, fertilization rate, fresh embryo transfer rate, and pregnancy rate.</p><p><strong>Results: </strong>A significantly lower rate of PPE was observed in the CFA group compared with the control group [2/56 (3.6%) versus 12/54 (22.2%), respectively]. CFA stimulation was associated with an 89% reduction in the odds of PPE (OR 0.11, 95% CI 0.02-0.55; P = 0.007). Fresh embryo transfer was achieved in 34/52 (65%) patients in the CFA group versus 21/48 (44%) patients in the control group (P = 0.04).</p><p><strong>Conclusions: </strong>Ovarian stimulation with long-acting CFA plus daily 150 IU r-FSH significantly reduced the risk of PPE and increased the feasibility of fresh embryo transfer in patients with low ovarian reserve. This strategy may offer a better approach for managing PPE, and may improve overall IVF success for this specific patient population.</p>","PeriodicalId":21134,"journal":{"name":"Reproductive biomedicine online","volume":"52 3","pages":"105270"},"PeriodicalIF":3.5,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146119918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The endometrium: is thickness all that counts? 子宫内膜:厚度是最重要的吗?
IF 3.5 2区 医学 Q1 OBSTETRICS & GYNECOLOGY Pub Date : 2025-09-26 DOI: 10.1016/j.rbmo.2025.105277
Paul Pirtea , Baris Ata
The commonly used 7 mm threshold for endometrial thickness in assisted reproductive technology lacks strong evidence and stems from outdated data. Recent studies show that live birth outcomes are comparable even with linings of less than 7 mm, particularly when using euploid embryos. Measurement variability, confounding factors and differing clinical practices limit the reliability of endometrial thickness as a standalone predictor. While extremely thin linings may warrant further evaluation, rigid cut-off values are unjustified. Endometrial thickness should be integrated into a broader, individualized assessment rather than drive clinical decisions in isolation.
辅助生殖技术中常用的7毫米子宫内膜厚度阈值缺乏强有力的证据,并且源于过时的数据。最近的研究表明,即使衬里小于7毫米,特别是使用整倍体胚胎时,活产结果也相当。测量变异性、混杂因素和不同的临床实践限制了子宫内膜厚度作为独立预测因子的可靠性。虽然极薄的前景可能值得进一步评估,但严格的截止值是不合理的。子宫内膜厚度应纳入更广泛的个体化评估,而不是孤立地推动临床决策。
{"title":"The endometrium: is thickness all that counts?","authors":"Paul Pirtea ,&nbsp;Baris Ata","doi":"10.1016/j.rbmo.2025.105277","DOIUrl":"10.1016/j.rbmo.2025.105277","url":null,"abstract":"<div><div>The commonly used 7 mm threshold for endometrial thickness in assisted reproductive technology lacks strong evidence and stems from outdated data. Recent studies show that live birth outcomes are comparable even with linings of less than 7 mm, particularly when using euploid embryos. Measurement variability, confounding factors and differing clinical practices limit the reliability of endometrial thickness as a standalone predictor. While extremely thin linings may warrant further evaluation, rigid cut-off values are unjustified. Endometrial thickness should be integrated into a broader, individualized assessment rather than drive clinical decisions in isolation.</div></div>","PeriodicalId":21134,"journal":{"name":"Reproductive biomedicine online","volume":"52 3","pages":"Article 105277"},"PeriodicalIF":3.5,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146038315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Outside Back Cover - Editorial Board 封底外-编辑委员会
IF 3.5 2区 医学 Q1 OBSTETRICS & GYNECOLOGY Pub Date : 2025-09-26 DOI: 10.1016/S1472-6483(25)00465-1
{"title":"Outside Back Cover - Editorial Board","authors":"","doi":"10.1016/S1472-6483(25)00465-1","DOIUrl":"10.1016/S1472-6483(25)00465-1","url":null,"abstract":"","PeriodicalId":21134,"journal":{"name":"Reproductive biomedicine online","volume":"51 4","pages":"Article 105258"},"PeriodicalIF":3.5,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145157648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inside Front Cover - Affiliations and First page of TOC 内部封面-附属机构和第一页的TOC
IF 3.5 2区 医学 Q1 OBSTETRICS & GYNECOLOGY Pub Date : 2025-09-26 DOI: 10.1016/S1472-6483(25)00452-3
{"title":"Inside Front Cover - Affiliations and First page of TOC","authors":"","doi":"10.1016/S1472-6483(25)00452-3","DOIUrl":"10.1016/S1472-6483(25)00452-3","url":null,"abstract":"","PeriodicalId":21134,"journal":{"name":"Reproductive biomedicine online","volume":"51 4","pages":"Article 105245"},"PeriodicalIF":3.5,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145157649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Front Matter - Continued TOC 正面物质-继续TOC
IF 3.5 2区 医学 Q1 OBSTETRICS & GYNECOLOGY Pub Date : 2025-09-26 DOI: 10.1016/S1472-6483(25)00453-5
{"title":"Front Matter - Continued TOC","authors":"","doi":"10.1016/S1472-6483(25)00453-5","DOIUrl":"10.1016/S1472-6483(25)00453-5","url":null,"abstract":"","PeriodicalId":21134,"journal":{"name":"Reproductive biomedicine online","volume":"51 4","pages":"Article 105246"},"PeriodicalIF":3.5,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145157650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Retraction notice to ‘The effect of vasopressin injection on ovarian reserve in patients who had cystectomy for ovarian endometrioma: a randomized controlled trial’ Reprod. Biomed. Online 44 (2022) 651-658 “抗利尿激素注射对卵巢子宫内膜异位瘤切除患者卵巢储备的影响:一项随机对照试验”的撤回通知。生物医学。44 (2022) 651-658
IF 3.5 2区 医学 Q1 OBSTETRICS & GYNECOLOGY Pub Date : 2025-09-26 DOI: 10.1016/j.rbmo.2025.105227
Saeed Alborzi , Tahereh Poordast , Elham Askary , Kefayat Chamanara , Ziba Zahiri Sorouri , Elnaz Hosseini Najar Kellaii , Siavash Pirzadeh Nahooji
{"title":"Retraction notice to ‘The effect of vasopressin injection on ovarian reserve in patients who had cystectomy for ovarian endometrioma: a randomized controlled trial’ Reprod. Biomed. Online 44 (2022) 651-658","authors":"Saeed Alborzi ,&nbsp;Tahereh Poordast ,&nbsp;Elham Askary ,&nbsp;Kefayat Chamanara ,&nbsp;Ziba Zahiri Sorouri ,&nbsp;Elnaz Hosseini Najar Kellaii ,&nbsp;Siavash Pirzadeh Nahooji","doi":"10.1016/j.rbmo.2025.105227","DOIUrl":"10.1016/j.rbmo.2025.105227","url":null,"abstract":"","PeriodicalId":21134,"journal":{"name":"Reproductive biomedicine online","volume":"51 4","pages":"Article 105227"},"PeriodicalIF":3.5,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145157647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Myo-inositol in reproductive management of women with PCOS: holy grail for medical practice or demon for scientific evidence? 肌醇在多囊卵巢综合征女性生殖管理中的作用:医学实践的圣杯还是科学证据的恶魔?
IF 3.5 2区 医学 Q1 OBSTETRICS & GYNECOLOGY Pub Date : 2025-09-18 DOI: 10.1016/j.rbmo.2025.105269
Stefano Palomba , Giuseppe Seminara , Antonio Aversa
Myo-inositol has gained widespread use in the management of infertility associated with polycystic ovary syndrome (PCOS), driven by its proposed role in improving insulin sensitivity and ovarian function. Despite its popularity in clinical practice, the evidence supporting myo-inositol’s efficacy in enhancing fertility outcomes remains limited and inconclusive. Current international and national guidelines do not endorse myo-inositol as a first-line treatment for PCOS-related infertility, either as monotherapy or in combination with ovulation induction agents. Even if early studies suggest potential benefits when used alongside clomiphene citrate or gonadotrophins, these findings are often outdated or misaligned with contemporary treatment protocols that favour letrozole and gonadotrophin-releasing hormone antagonist regimens. In the context of IVF, myo-inositol may reduce gonadotrophin requirements and improve some intermediate/secondary outcomes, although data on live births and long-term efficacy are lacking. This commentary critically evaluates the current literature on use of myo-inositol in PCOS fertility care, emphasizing the need for well-designed, adequately powered randomized controlled trials that reflect current clinical standards. Until stronger evidence is available, myo-inositol should not be routinely recommended in fertility protocols for PCOS but reserved for individualized cases within an evidence-based framework.
肌醇在改善胰岛素敏感性和卵巢功能方面的作用已被广泛应用于多囊卵巢综合征(PCOS)相关不孕症的治疗。尽管它在临床实践中很受欢迎,但支持肌醇在提高生育结果方面的功效的证据仍然有限且不确定。目前的国际和国家指南不支持肌醇作为pcos相关不孕症的一线治疗,无论是单独治疗还是与促排卵剂联合使用。即使早期研究表明与枸橼酸克罗米芬或促性腺激素联合使用有潜在的益处,但这些发现往往是过时的,或与支持来曲唑和促性腺激素释放激素拮抗剂方案的当代治疗方案不一致。在体外受精的情况下,肌醇可以减少促性腺激素的需求,改善一些中期/继发性结局,尽管缺乏活产和长期疗效的数据。这篇评论批判性地评价了目前关于肌醇在多囊卵巢综合征生育护理中使用的文献,强调需要设计良好、充分有力的随机对照试验,以反映当前的临床标准。在获得更有力的证据之前,肌醇不应常规推荐用于多囊卵巢综合征的生育方案,而应在循证框架内保留用于个体化病例。
{"title":"Myo-inositol in reproductive management of women with PCOS: holy grail for medical practice or demon for scientific evidence?","authors":"Stefano Palomba ,&nbsp;Giuseppe Seminara ,&nbsp;Antonio Aversa","doi":"10.1016/j.rbmo.2025.105269","DOIUrl":"10.1016/j.rbmo.2025.105269","url":null,"abstract":"<div><div>Myo-inositol has gained widespread use in the management of infertility associated with polycystic ovary syndrome (PCOS), driven by its proposed role in improving insulin sensitivity and ovarian function. Despite its popularity in clinical practice, the evidence supporting myo-inositol’s efficacy in enhancing fertility outcomes remains limited and inconclusive. Current international and national guidelines do not endorse myo-inositol as a first-line treatment for PCOS-related infertility, either as monotherapy or in combination with ovulation induction agents. Even if early studies suggest potential benefits when used alongside clomiphene citrate or gonadotrophins, these findings are often outdated or misaligned with contemporary treatment protocols that favour letrozole and gonadotrophin-releasing hormone antagonist regimens. In the context of IVF, myo-inositol may reduce gonadotrophin requirements and improve some intermediate/secondary outcomes, although data on live births and long-term efficacy are lacking. This commentary critically evaluates the current literature on use of myo-inositol in PCOS fertility care, emphasizing the need for well-designed, adequately powered randomized controlled trials that reflect current clinical standards. Until stronger evidence is available, myo-inositol should not be routinely recommended in fertility protocols for PCOS but reserved for individualized cases within an evidence-based framework.</div></div>","PeriodicalId":21134,"journal":{"name":"Reproductive biomedicine online","volume":"52 2","pages":"Article 105269"},"PeriodicalIF":3.5,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145842368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Reproductive biomedicine online
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1